PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Set to Capitalize on Growth of Dietary Supplement, Drug Delivery Markets
Two separate market research reports predict 7.0 percent and 2.9 percent CAGR, respectively, in PreveCeutical’s areas of operation PreveCeutical developing Sol-Gel, an innovative medicine delivery platform Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is uniquely positioned to capitalize of the growth of two different markets in which it currently operates: dietary supplements and drug delivery systems. Two separate market research reports indicated recently that these sectors are expected to grow a projected 7.0 percent and 2.9 percent, respectively, over the next five years. In a report published in May, Technavio estimated that the global dietary…